CISD2 and metabolic dysfunction-associated steatotic liver disease: Our previous study revealed that a half dose of the Cisd2 protein in mice is insufficient to carry out its normal functions in the liver, which can be described as a state of Cisd2 haploinsufficiency; these mice develop a phenotype similar to the clinical manifestations of NAFLD [16].